Education
About Us
Working with TipRanks
Follow Us
SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
RESEARCH TOOLSreports
SBTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range8.32p - 27.50p
Previous CloseN/A
Volume282.34K
Average Volume (3M)1.67M
Market Cap
£42.70M
Enterprise Value21.28M
Total Cash (Recent Filing)£1.24M
Total Debt (Recent Filing)£1.03M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Dec 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding258,779,450
10 Day Avg. Volume1,438,705
30 Day Avg. Volume1,666,208
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-16.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SkinBioTherapeutics News
PremiumCompany Announcements
SkinBioTherapeutics Secures UK Distribution Deal with Superdrug
PremiumCompany Announcements
David Brierwood Increases Stake in SkinBioTherapeutics
PremiumCompany Announcements
SkinBioTherapeutics Raises £4.2 Million Through Share Issuance
PremiumCompany Announcements
SkinBioTherapeutics Secures Superdrug Deal and Raises £4.1m
PremiumCompany Announcements
SkinBioTherapeutics Appoints New Adviser and Broker
PremiumCompany Announcements
SkinBioTherapeutics Announces Change in Major Holdings
PremiumCompany Announcements
SkinBioTherapeutics Announces Change in Voting Rights StructureSBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 8.32p and its highest was 27.50p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £42.70M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 04, 2025 which is in 151 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
SkinBioTherapeutics PLC released its earnings results on Mar 26, 2025. The company reported -0.005p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005p.
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 258,779,450 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
SkinBioTherapeutics PLC reported an EPS of -0.005p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
SkinBioTherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.11%
12-Months-Change
Fundamentals
Return on Equity
-63.28%
Trailing 12-Months
Asset Growth
73.26%
Trailing 12-Months
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Technical Analysis
Futura Medical
―
OptiBiotix Health
―
Sareum Holdings
―
Tissue Regenix
―
Ondine Biomedical, Inc.
―